116686-84-1

Basic information

• Product Name: 3'-chloro-4-nitroacetophenone
• Synonyms: 3'-chloro-4-nitroacetophenone
• CAS NO: 116686-84-1
• Molecular Weight: 199.594
• Mol File: 116686-84-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3'-chloro-4-nitroacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-chloro-4-nitroacetophenone(116686-84-1)
• EPA Substance Registry System: 3'-chloro-4-nitroacetophenone(116686-84-1)

Safety Data

• Hazardous Substances Data: 116686-84-1(Hazardous Substances Data)

Upstream product

• 99-02-5 3'-Chloroacetophenone 
• 6953-83-9 1-(4-amino-3-chlorophenyl)ethan-1-one 
• 1317-39-1 copper(I) oxide 

Downstream Products

• 119982-88-6 1-[4-Nitro-3-(thiophen-2-ylsulfanyl)-phenyl]-ethanone 
• 119982-92-2 1-[3-(2-Methoxy-phenylsulfanyl)-4-nitro-phenyl]-ethanone 
• 116687-49-1 1-(4-Nitro-3-o-tolyloxy-phenyl)-ethanone 
• 116686-59-0 4'-(2-amino-4-thiazolyl)-2'-(2,4-difluorophenoxy)methanesulfonanilide 
• 116687-44-6 2-methyl-2-[4-nitro-3-(2,4,6-trichlorophenoxy)phenyl]-1,3-dioxolane 
• 116687-25-3 2-[3-(2,6-dichlorophenoxy)-4-nitrophenyl]-2-methyl-1,3-dioxolane 
• 146139-79-9 2-[3-(2,4-Difluoro-phenoxy)-4-nitro-phenyl]-2-methyl-[1,3]dioxolane 
• 116687-65-1 4'-bromoacetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide 
• 116686-15-8 N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide 
• 116687-45-7 4'-nitro-3'-(2,4,6-trichlorophenoxy)acetophenone 

Relevant articles and documents

SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES

A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or ORR, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).

Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same

This invention relates to new alkane-sulfonanilide derivatives of the formula: STR1 wherein R1, R2 and R8 are each hydrogen, cyano, halogen, lower alkyl, halo (lower) alkyl, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl or lower alkoxy, R3 is lower alkyl, R4 is acyl, cyano, carboxy, hydroxy(lower)-alkyl, mercapto, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, 5-membered unsaturated heterocyclic group which may have amino, lower alkanoylamino, lower alkylthio or lower alkylsulfonyl, phenylthio which may have nitro or amino, lower alkanoyl(lower)alkenyl or a group of the formula: STR2 wherein R6 is hydrogen, amino or lower alkyl and R7 is hydroxy, lower alkoxy, carboxy(lower)alkoxy, lower alkoxycarbonyl(lower)alkoxy, ureido or thioureido, and R5 is hydrogen, halogen, lower alkyl or lower alkanoyl, and pharmaceutically acceptable salts thereof. More particularly, it relates to alkanesulfonanilide derivatives and pharmaceutically acceptable salts thereof which have antiinflammatory activities and analgesic activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the treatment of inflammatory disease or pains in human being and animals".